Search
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.
Synonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Categories: Cytochrome P-450 CYP2B6 Inducers, Heterocyclic Compounds, 1-RingNizatidine
go.drugbank.com/drugs/DB00585ApprovedA histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingSynonyms: N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylaminePerflubutane
go.drugbank.com/drugs/DB12821ApprovedInvestigationalWithdrawnIt is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease. … Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease.
Categories: Compounds used in a research, industrial, or household settingPosaconazole
go.drugbank.com/drugs/DB01263ApprovedInvestigationalVet approvedPosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: NOXAFIL ® TABLETAS RECUBIERTAS DE LIBERACIÓN RETARDADA, Posaconazole SpPlicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnPlicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. … It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Categories: Compounds used in a research, industrial, or household settingNitrendipine
go.drugbank.com/drugs/DB01054ApprovedWithdrawnNitrendipine is a calcium channel blocker with marked vasodilator action. … It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
Mixtures: ENEAS® 10/20 MG COMPRIMIDOS, ENEAS® 10/20 MG COMPRIMIDOSCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesVorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144] … [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.
Synonyms: 1,3,5-triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-n2,n4-bis((1r)-2,2,2-trifluoro-1-methylethyl)-Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesDecamethonium
go.drugbank.com/drugs/DB01245ApprovedIt is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor. … Decamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant.
Synonyms: N,N,N,N',N',N'-hexamethyl-1,10-decanediaminiumNilvadipine
go.drugbank.com/drugs/DB06712ApprovedNilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: Tensan retard 8 mg - KapselnDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigational[A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. … Most recently, in November 2025, the subcutaneous formulation received approval as a monotherapy for the treatment of adult patients with high-risk smoldering multiple myeloma. [L54658]
Products: Darzalex Sc, DARZALEX® SC 120 MG/ML SOLUCIÓN INYECTABLE